LeMaitre Vascular

LeMaitre Vascular, Inc. engages in the provision of medical devices and human tissue cryopreservation services. The company focuses on the design, marketing, sales, service, and technical support of medical devices and implants for the treatment of peripheral vascular disease. Its products include balloon catheters, carotid shunts, biologic patches, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, vascular grafts, and powered phlebectomy. The company was founded by George D. LeMaitre on November 28, 1983 and is headquartered in Burlington, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

LeMaitre Vascular reports solid Q4 performance and eyes growth

LeMaitre Vascular's Q4 2022 performance showed growth in sales and income, with strong guidance for 2023.
Despite challenges with gross margin and product line issues, the company is well-positioned for future growth.
Opportunities lie in M&A, sales force expansion, and improving operational efficiency.
Strategic investments have bolstered the company's ability to meet demand and regulatory requirements.

LeMaitre Vascular reports robust Q1 sales and eyes Asia expansion

LeMaitre Vascular delivered strong sales and operating income in Q1 2023, driven by pricing strategies and market expansion efforts.
While facing challenges like rising expenses and competitor risks, the company aims to maintain profitability and drive growth through strategic initiatives.
Opportunities in Asia Pacific expansion and the Aziyo distribution agreement offer avenues for revenue growth and margin improvement.
Overall, LeMaitre's focus on maintaining margins, exploring new markets, and product innovation positions it for continued success in 2023.

LeMaitre Vascular reports robust Q2 sales growth and eyes international expansion

LeMaitre Vascular's Q2 performance reflects strong sales growth, pricing power, and operational efficiency, positioning the company for future success.
While facing margin challenges, the company's diversified product portfolio, international expansion plans, and solid cash position present growth opportunities.
Strategic focus on addressing challenges, optimizing operations, and capitalizing on growth opportunities will be crucial for sustained success and market leadership.

LeMaitre Vascular excels in Q3, eyes growth opportunities ahead

LeMaitre Vascular's Q3 performance was strong, with growth in sales and margins.
The company faces challenges in international markets and sales and marketing dynamics.
Opportunities lie in pricing strategies, product focus, and upcoming product filings.
Overall, LeMaitre Vascular is well-positioned for growth and strategic acquisitions.

LeMaitre Vascular posts strong Q4 results, eyes global expansion opportunities

LeMaitre Vascular's strong performance in Q4 2023 showcases robust sales growth and margin improvement.
While facing challenges such as ongoing impacts from the pandemic and tax rate assumptions, the company is well-positioned for growth.
Strategic initiatives like sales force expansion, APAC expansion, and M&A activities align with opportunities for market penetration and revenue growth.
Guidance for 2024 indicates a focus on operational efficiency and growth strategies to drive continued success.

LeMaitre Vascular excels in Q1 2024, eyes European expansion

Overall, LeMaitre Vascular's Q1 performance showcases strong financial growth, operational improvements, and strategic positioning for future success. The company's focus on expanding its market presence and product approvals sets a positive outlook for continued growth and profitability.

LeMaitre Vascular (LMAT) reports strong Q3 performance and eyes APAC growth

LeMaitre Vascular (LMAT) demonstrated robust sales growth, operational strength, and strategic focus in Q3 2024, positioning itself for continued success. Challenges include pricing strategies and leadership transition, while opportunities exist in sales expansion, regulatory milestones, and strategic initiatives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zimmer Biomet Hlds

ZBH vs. LMAT: Which Stock Is the Better Value Option?

BURLINGTON, Mass., March 14, 2023 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants and services, today announced that it has signed a definitive agreement to buy out its Thai distributor, Prompt Serve, for $688,000. In 2022 Prompt Serve purchased $950,000 of LeMaitre devices which it then sold to Thai hospitals for approximately $1.5mm. LeMaitre expects to establish a Bangkok office/warehouse and to begin selling directly to Thai hospitals in H2 2023. This will be LeMaitre's 29th direct-to-hospital country and follows LeMaitre's Korean distributor buyout in 2022. Korea and Thailand were previously LeMaitre's two largest international distributors.

LeMaitre to Go Direct in Thailand

LeMaitre Vascular's results were mixed in the fourth quarter. The company could maintain high dividend growth moving forward.

Buy This Under-the-Radar Stock for Dividend Growth

Reasonable growth vertically throughout P&L and cash flows, exhibiting strength in major markets. Growth in rep headcount converting at the top line looks to further growth in reps in FY23.

LeMaitre: Remaining Constructive On Long-Term Valuations

Assured Guaranty

Blackrock Inc

BWX Technologies

Commerce Bancshares

Cogent Communications Holdings

Canadian National Railway Company

eBay

Elevance Health Inc

Equinix

Evans Bancorp

Exponent

Comfort Systems USA

Genpact

Gaming and Leisure Properties

Home Depot

Jack Henry & Associates

Kforce

Kimberly-Clark

L3Harris

Louisiana-Pacific

Northrim BanCorp

Public Service Enterprise Group

Perrigo

All stocks have at least five fiscal years of dividend growth history and come from the U.S. Dividend Champions List. They have an average increase of 8.3% and a median increase of 8.1%.

32 Upcoming Dividend Increases Including 2 Dividend Kings

LeMaitre Vascular, Inc. (NASDAQ:LMAT ) Q4 2022 Earnings Conference Call February 23, 2023 5:00 PM ET Company Participants J.J. Pellegrino - Chief Financial Officer George LeMaitre - Chairman and Chief Executive Officer Dave Roberts - President Conference Call Participants Matthew Mishan - KeyBanc Michael Petusky - Barrington Research Brooks O'Neil - Lake Street Capital Jim Sidoti - Sidoti Operator Welcome to LeMaitre Vascular Q4 2022 Financial Results Conference Call.

LeMaitre Vascular, Inc. (LMAT) Q4 2022 Earnings Call Transcript

LeMaitre (LMAT) delivered earnings and revenue surprises of -3.85% and 0.57%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

LeMaitre Vascular (LMAT) Q4 Earnings and Revenues Lag Estimates

BURLINGTON, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q4 2022 results, announced a $0.14/share quarterly dividend (+12%) and provided guidance.

LeMaitre Q4 2022 Financial Results

BURLINGTON, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its fourth quarter 2022 financial results on Thursday, February 23, 2023, after the market close. The company has scheduled a conference call for 5:00 PM ET the same day to discuss the results, business highlights, and company outlook.

LeMaitre Will Announce Fourth Quarter 2022 Earnings Results February 23, 2023

Varex Imaging

VREX vs. LMAT: Which Stock Is the Better Value Option?

LeMaitre Vascular isn't well-known to investors. But vascular surgeons do know the company well.

Is This Small-Cap Dividend Stock a Buy?

EssilorLuxottica SA

ESLOY vs. LMAT: Which Stock Is the Better Value Option?

ESLOY vs. LMAT: Which Stock Should Value Investors Buy Now?

Missed top line estimates secondary to FX headwinds and market challenges. Balance sheet remains healthy with adequate cash to deploy for acquisitions, sales rep investments.

LeMaitre: Balance Sheet Ready To Unlock Risk Capital, Reaffirm Buy

The medical device maker flies under the radar of most investors.

Is This Underfollowed Dividend Stock a Buy?

BURLINGTON, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it is participating in two upcoming investor conferences.

LeMaitre to Present at Upcoming Investor Conferences

LeMaitre (LMAT) delivered earnings and revenue surprises of -10.71% and 2.75%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

LeMaitre Vascular (LMAT) Misses Q3 Earnings and Revenue Estimates

LeMaitre Vascular, Inc. (NASDAQ:LMAT ) Q3 2022 Results Conference Call October 27, 2022 5:00 PM ET Company Participants J.J. Pellegrino - Chief Financial Officer David Roberts - President Conference Call Participants Michael Sarcone - Jefferies Brooks O'Neil - Lake Street Capital Purnima Malik - Stifel Michael Petusky - Barrington Research James Sidoti - Sidoti & Company Scott Henry - ROTH Capital Javier Fonseca - Spartan Capital Operator Good day, and welcome to the LeMaitre Vascular Incorporated's Third Quarter 2022 Earnings Conference Call.

LeMaitre Vascular, Inc. (LMAT) Q3 2022 Earnings Call Transcript

BURLINGTON, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q3 2022 results, announced a $0.125/share quarterly dividend and provided guidance.

LeMaitre Q3 2022 Financial Results

LeMaitre (LMAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: LeMaitre Vascular (LMAT) Q3 Earnings Expected to Decline

BURLINGTON, Mass., Oct. 17, 2022 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its third quarter 2022 financial results on Thursday, October 27, 2022, after the market close. The company has scheduled a conference call for 5:00 PM ET the same day to discuss the results, business highlights, and company outlook.

LeMaitre Will Announce Third Quarter 2022 Earnings Results October 27, 2022

We reiterate the buy call on LeMaitre Vascular. The company's capital management strategies continue to yield double-digit ROI from its invested capital.

LeMaitre Vascular: Reiterate Buy Thesis Following Strong Q2 Numbers

BURLINGTON, Mass., Aug. 31, 2022 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that David Roberts, President, will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Wednesday, September 14, 2022, at 4:40 PM ET at the Sheraton New York Hotel, New York.

LeMaitre to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

ZBH vs. LMAT: Which Stock Should Value Investors Buy Now?

BURLINGTON, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that JJ Pellegrino, Chief Financial Officer, will present at the Canaccord Genuity 42nd Annual Growth Conference on Thursday, August 11, 2022, at 12:00 PM ET at the InterContinental Hotel, Boston.

News for LeMaitre Vascular Stock (LMAT)